I'd have to say Moderna, which is 11 years old and also publicly traded, but should qualify because of how recently they actually brought their first product to market.<p>Considering every non-cash asset is wildly over-valued right now, I don't know that I believe <i>any</i> non-health startup (that I've heard of) is undervalued.<p>I have a lot of faith in Rivian, for example, but they're valued ar $80B before even selling a single vehicle. Look at what happened to Workhorse if you think that's reasonable.<p>Moderna's market cap is only $170B, which seems low considering their potential to make hundreds of billions annually if they find even one new application of mRNA technology (e.g. cancer treatment).